About Akcea Therapeutics (NASDAQ:AKCA)
Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease due to elevated triglyceride levels. It has strategic collaboration with Novartis Pharma AG. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Akcea Therapeutics, Inc. is a subsidiary of Ionis Pharmaceuticals, Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202
Debt
Debt-to-Equity RatioN/A
Current Ratio3.30%
Quick Ratio3.30%
Price-To-Earnings
Trailing P/E Ratio-11.36
Forward P/E Ratio-20.02
P/E GrowthN/A
Sales & Book Value
Annual Sales$55.21 million
Price / Sales31.93
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book9.79
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees100
Outstanding Shares66,720,000
Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions
What is Akcea Therapeutics' stock symbol?
Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."
How were Akcea Therapeutics' earnings last quarter?
Akcea Therapeutics (NASDAQ:AKCA) posted its quarterly earnings results on Monday, February, 26th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.03. The firm earned $18.04 million during the quarter, compared to analyst estimates of $15.48 million. View Akcea Therapeutics' Earnings History.
What price target have analysts set for AKCA?
4 analysts have issued 1 year price targets for Akcea Therapeutics' shares. Their predictions range from $20.00 to $30.00. On average, they anticipate Akcea Therapeutics' stock price to reach $26.6667 in the next twelve months. View Analyst Ratings for Akcea Therapeutics.
Who are some of Akcea Therapeutics' key competitors?
Some companies that are related to Akcea Therapeutics include Array Biopharma (ARRY), Tesaro (TSRO), Clovis Oncology (CLVS), Amicus Therapeutics (FOLD), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Evotec A.G. (EVTCY), Acadia Pharmaceuticals (ACAD), Supernus Pharmaceuticals (SUPN), Puma Biotechnology (PBYI), Akorn (AKRX), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), The Medicines (MDCO), AnaptysBio (ANAB) and Portola Pharmaceuticals (PTLA).
Who are Akcea Therapeutics' key executives?
Akcea Therapeutics' management team includes the folowing people:
- Ms. Paula Soteropoulos, CEO, Pres & Director (Age 50)
- Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 45)
- Dr. Louis St. Laurence O'Dea MB, BCh, BAO, FRCP(C), Chief Medical Officer, Exec. VP & Head of Regulatory Affairs (Age 67)
- Mr. Michael F. MacLean, Chief Financial Officer (Age 52)
- D. Wade Walke Ph.D., VP of Corp. Communications & Investor Relations
When did Akcea Therapeutics IPO?
(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.
Has Akcea Therapeutics been receiving favorable news coverage?
News stories about AKCA stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akcea Therapeutics earned a media sentiment score of 0.04 on Accern's scale. They also assigned news articles about the company an impact score of 46.33 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Akcea Therapeutics?
Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akcea Therapeutics' stock price today?
One share of AKCA stock can currently be purchased for approximately $26.42.
How big of a company is Akcea Therapeutics?
Akcea Therapeutics has a market capitalization of $1.61 billion and generates $55.21 million in revenue each year. The company earns $-109,750,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis. Akcea Therapeutics employs 100 workers across the globe.
How can I contact Akcea Therapeutics?
Akcea Therapeutics' mailing address is 55 CAMBRIDGE PARKWAY SUITE 100, CAMBRIDGE MA, 92010. The company can be reached via phone at 617-207-0202 or via email at [email protected]
MarketBeat Community Rating for Akcea Therapeutics (AKCA)
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Akcea Therapeutics (NASDAQ:AKCA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Akcea Therapeutics (NASDAQ AKCA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.70%
Institutional Ownership Percentage: 29.10%
Akcea Therapeutics (NASDAQ AKCA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/17/2018 | Ionis Pharmaceuticals Inc | Major Shareholder | Buy | 10,666,666 | $18.75 | $199,999,987.50 | 53,447,879 |  |
| 7/19/2017 | Ionis Pharmaceuticals Inc | Major Shareholder | Buy | 3,125,000 | $8.00 | $25,000,000.00 | 28,884,540 | |
(Data available from 1/1/2013 forward)
Akcea Therapeutics (NASDAQ AKCA) News Headlines
| Source: |
|
Akcea Therapeutics (NASDAQ:AKCA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Akcea Therapeutics (NASDAQ:AKCA) Income Statement, Balance Sheet and Cash Flow Statement
Akcea Therapeutics (NASDAQ AKCA) Stock Chart for Friday, April, 20, 2018
Loading chart…
